Browse studies
Find your next paid study
52 recruiting studies matching your filters
Phase 2
TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line trea…
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Estimated
~$10 – $6,250
Brown UniversityNCT07502872
Phase 2
Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) …
Diffuse Large B Cell Lymphoma (DLBCL)
Estimated
~$10 – $6,250
Medical College of WisconsinNCT06594939
Phase 2
A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma
This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for prim…
Primary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-Cell Lymphoma Refractory+3 more
Estimated
~$10 – $7,500
Jennifer Crombie, MDNCT05934448
Phase 2
A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…
Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more
Estimated
~$10 – $7,500
Seda S. ToluNCT07283822